According to the 2016 World Health Organization Classification of Tumors of the Central Nervous System (2016 CNS WHO), IDH-mutant astrocytic gliomas comprised WHO grade II diffuse astrocytoma, IDH-mutant (AII IDHmut ), WHO grade III anaplastic astrocytoma, IDH-mutant (AAIII IDHmut ), and WHO grade IV glioblastoma, IDH-mutant (GBM IDHmut ). Notably, IDH gene status has been made the major criterion for classification while the manner of grading has remained unchanged: it is based on histological criteria that arose from studies which antedated knowledge of the importance of IDH status in diffuse astrocytic tumor prognostic assessment. Several studies have now demonstrated that the anticipated differences in survival between the newly defined AII IDHmut and AAIII IDHmut have lost their significance. In contrast, GBM IDHmut still exhibits a significantly worse outcome than its lower grade IDH-mutant counterparts. To address the problem of establishing prognostically significant grading for IDH-mutant astrocytic gliomas in the IDH era, we undertook a comprehensive study that included assessment of histological and genetic approaches to prognosis in these tumors. A discovery cohort of 211 IDH-mutant astrocytic gliomas with an extended observation was subjected to histological review, image analysis, and DNA methylation studies. Tumor group-specific methylation profiles and copy number variation (CNV) profiles were established for all gliomas. Algorithms for automated CNV analysis were developed. All tumors exhibiting 1p/19q codeletion were excluded from the series. We developed algorithms for grading, based on molecular, morphological and clinical data. Performance of these algorithms was compared with that of WHO grading. Three independent cohorts of 108, 154 and 224 IDH-mutant astrocytic gliomas were used to validate this approach. In the discovery cohort several molecular and clinical parameters were of prognostic relevance. Most relevant for overall survival (OS) was CDKN2A/B homozygous deletion. Other parameters with major influence were necrosis and the total number of CNV. Proliferation as assessed by mitotic count, which is a key parameter in 2016 CNS WHO grading, was of only minor influence. Employing the parameters most relevant for OS in our discovery set, we developed two models for grading these tumors. These models performed significantly better than WHO grading in both the discovery and the validation sets. Our novel algorithms for grading IDH-mutant astrocytic gliomas overcome the challenges caused by introduction of IDH status into the WHO classification of diffuse astrocytic tumors. We propose that these revised approaches be used for grading of these tumors and incorporated into future WHO criteria.
Introduction
Diffuse astrocytic gliomas are the most common brain tumors of adults and their grading has, therefore, been of considerable significance in the management of patients with brain tumors. As a result, over the years, these tumors have been graded according to various systems, each representing an advance over prior approaches. These have included the Kernohan scheme, the St. Anne-Mayo system and, for the past 25 years, primarily the WHO classification [8, 12, 13] . These schemes often resulted in patient groups with significantly varying prognoses that received treatments of differing intensity. In recent years, the WHO classification scheme based on early work from Zulch [38] and regarding astrocytic gliomas from Burger et al. [3] has been most widely used [13, 14] .
IDH1 and IDH2 mutations have emerged as early mutations in diffuse astrocytic tumors [2, 21, 35, 37] , and determination of the IDH status by immunohistochemistry [6] or sequencing has now become a standard in the diagnosis of these tumors. The 2016 WHO Classification of Tumors of the Central Nervous System [14] introduced molecular parameters for the categorization of diffuse astrocytomas, notably IDH mutation status [14] . In fact, determination of IDH and 1p/19q status is mandatory for diagnosing beyond NOS (not otherwise specified) categories. However, applying the new classification parameters results in patient groups that are different from those classified prior to the 2016 CNS WHO (e.g. according to the 2007 CNS WHO). From the former group of diffuse WHO grade II and III astrocytomas, approximately 70-80% now are classified as diffuse astrocytoma, IDH-mutant (AII IDHmut ) and anaplastic astrocytoma, IDH-mutant (AAIII IDHmut ) while 20-30% are classified as diffuse astrocytoma, IDHwildtype (AII IDHwt ) and anaplastic astrocytoma, IDHwildtype (AAIII IDHwt ). In turn, the shifting of diagnostic groups has prognostic implications. For example, multiple studies have demonstrated a close relationship between many AII IDHwt /AAIII IDHwt to glioblastoma, IDH-wildtype (GBM IDHwt ) [4, 27, 33] . In fact, prior to the 2016 CNS WHO the prognostic power of grading parameters for diffuse astrocytoma WHO grade II (AII NOS ) and anaplastic astrocytoma WHO grade III (AAIII NOS ) was most likely a result of considerable contamination with unrecognized GBM IDHwt [34] . In addition, a series of recent studies has highlighted that WHO grading of AII IDHmut /AAIII IDHmut has lost its prognostic relevance [4, 18, 20, 22, 28, 33, 34] . Given the clinical importance of appropriate grading, the potential prognostic changes brought about by the 2016 CNS WHO classification pose a major challenge.
We, therefore, sought to establish novel, improved grading criteria for IDH-mutant astrocytic gliomas.
Methods

Study design and participants
For this multicenter retrospective analysis we collected a discovery series of 211 astrocytic tumors. We defined the following criteria for inclusion: (1) all tumors had either an IDH1 or an IDH2 mutation; (2) all tumors had a 2016 CNS WHO integrated diagnosis of AII IDHmut (n = 54), AAIII IDHmut (n = 90) or GBM IDHmut (n = 67), i.e., no tumors had 1p/19q codeletion; (3) sufficient formalin-fixed, paraffin-embedded (FFPE) material for morphological and additional molecular analyses was available; and (4) the patients had an extended follow-up. Tumor material was from the archive of the Department of Neuropathology, University of Heidelberg, Heidelberg, Germany and from patients enrolled in the NOA04 trial [36] . Use of tissue and clinical data were in accordance with local ethical regulations.
Three validation series were compiled. The first validation series from Heidelberg (HD) containing 108 tumors differed from the discovery set only in that sufficient material for the complete set of analyses performed on the discovery set was not available. The HD validation series contained AII IDHmut (n = 32), AAIII IDHmut (n = 29) and GBM IDHmut (n = 47). In this set diagnosis and grading according to the guidelines of the 2016 CNS WHO was performed (AvD). The second validation set from the European Organization for Research and Treatment of Cancer (EORTC) contained 154 cases and was compiled from patients of the EORTC studies 22,033 (64 cases), 26091 (80 cases) and 26,981 (10 cases) with Illumina 450k or 850k/EPIC data being available. All patients in this set also had an IDH mutation and none of the tumors harbored a 1p/19q codeletion. The EORTC validation series contained AII IDHmut (n = 94), AAIII IDHmut (n = 39) and GBM IDHmut (n = 21). In this set diagnosis and grading according to the guidelines of the 2016 CNS WHO was performed by reference centers. The third validation set from The Cancer Genome Atlas consortium (TCGA) contained 224 cases and was retrieved from published data. In this set diagnosis and grading was obtained from the source. Methylome data based on Illumina 450k array was available for all of these cases. All cases in this set had an IDH mutation as provided by TCGA and none contained a 1p/19q codeletion as assessed by copy number profiles which were calculated from the DNA methylation data. Clinical data were known to the local investigators (MS, TO, DSt, DSc, AvD). Cases from the HD validation set also were reviewed by the same neuropathologist (AvD). Clinical data from the HD validation set were known to the lead authors. Clinical data from the EORTC validation set were not known to the lead authors. Clinical data for the TCGA validation set were open access. The institutional funding of this study did not influence study design, inclusion criteria, analyses or interpretation of the data. MS, TO, DSt, DSc and AvD had full access to all raw data except for the EORTC series and had final responsibility for the decision to submit for publication.
Procedures
For the discovery set, 4 µm sections were cut from FFPE blocks from all tumors and stained with hematoxylin/eosin, and examined by immunohistochemistry with antibodies against IDH1 R132H (clone H09, Dianova, Hamburg, Germany), Ki-67 (clone MIB-1, Dako, Waldbronn, Germany) or pHH3 (rabbit polyclonal, BioCare Medical, Pacheco, USA) to determine proliferation and CD31 (clone JC70A, Dako, Waldbronn, Germany) to determine vascular density.
All tumor samples were analyzed by Illumina HumanMethylation450 (450k) or MethylationEPIC (850k) arrays (Illumina, San Diego, CA, USA) as previously described [32] . Methylation data were analyzed by a classifier as previously reported [5] . CNV plots were generated using the R/ Bioconductor package conumee version 1.6.0. Automated assessment of copy-number changes was performed using a proprietary algorithm (Stichel D and colleagues, unpublished). This allowed determining CNV load (CNV-L) for each tumor.
The discovery set was subjected to digital image analysis. Parameters assessed included cell count, proliferation activity and microvessel density. The software package Aperio ImageScope was employed for proliferation and microvessel density analysis. The software packages Ilastik [31] and ImageJ [30] were used for cell count analysis. To receive subgroups with distinct OS, conditional trees were created applying the function ctree from the R package party on the discovery set and a set of selected input variables. Here, the global null hypothesis of independence between any of the input variables and the OS was tested. If it could not be rejected, the association of any single input variable with the response was computed as p value from a test for the partial null hypothesis of the variable and OS. The input variable with the highest association to OS was selected and a binary split in this variable was created. This procedure was then repeated to create conditional trees. To create Model path all parameters received from molecular analyses but CDKN2A/B status were excluded. Kaplan-Meier estimators were computed using the function survfit from the R package survival. All parameters assessed are listed in Table 1 
Statistical analysis
All patient sets were retrospectively compiled. The size of the respective sets was determined by availability of data and not by a power calculation. OS times were analyzed by the Kaplan-Meier method and compared with a log-rank test. Prediction error plots were based on Brier scores. p values less than 0.05 were considered significant. Software R version 3.4 and packages survival and party were employed for analysis. The morphological parameters of strongest negative prognostic value were vascular proliferation (p < 0.0005) and necrosis (p < 0.00005). Patients aged 55 and older did worse (p < 0.04) than patients aged below this cutoff confirming the influence of age on OS. Female patients fared significantly (p = 0.01) better than male patients. Image analysis showed that cellularity had a major association with OS. Cell count defined as number of tumor cells per square millimeter in the tumor area of highest density emerged as an important parameter for prognostic evaluation. Patients with a cell density of 4605/mm 2 or more fared worse than patients with 4604 or fewer tumor cells/mm 2 (p < 0.002). Ki-67 immunohistochemistry was significantly associated with worse OS (cutoff 14.5%; p < 0.006), however, mitotic count established by assessing sections treated with pHH3 antibody was not prognostic (Table 1) . While pHH3 has been established as a reliable marker for assessing mitotic activity, those studies have mainly been performed prior to further stratification of diffuse astrocytomas by IDH status [7] . In a recent study on IDH-mutant diffuse glioma, pHH3 was found to reliably detect mitotic figures but turned out with a weaker association with survival than Ki-67 [10] .
EPIC-or 450k array data were employed to assess several parameters: this included analysis by the brain tumor classifier tool [5] for the confirmation of IDH mutations and evaluation of individual copy number status. Copy number plots were evaluated for amplifications or homozygous deletions, respectively. In the discovery set regions with such alterations contained CCND1, CCND2, CDK4, CDK6, CDKN2A/B, EGFR, MDM4, MET, MYC, MYCN, NF1, NF2, PDGFR2, PPM1D, PTEN, RB1 and SMARCB1 (Table 2) . Upon univariate analysis, the strongest association with OS was observed for homozygous CDKN2A/B deletion and for MYCN amplification (Table 2 and Fig. 1b) . Furthermore, the total CNV-load (CNVL) was determined, resulting in a split for a value of 349,695,798 base pairs (rounded 350 Mb). This number refers to the sum of all gains or deletions as determined by analysis of the 450k/850k raw data by our proprietary algorithm.
Patients with higher CNVL fared significantly worse than patients with lower CNVL (p < 0.0001). However, the frequency for all chromosomal gains or losses increased with age as demonstrated by summary CNV plots (supplementary figure 1) . Further, EPIC/450k array methylation data were used for unsupervised clustering of the discovery dataset. This analysis yielded two sets with highly significant differences in OS (supplementary figure 2a) . Likewise, the algorithm underlying our methylation based classifier [5] recognized two sets with significantly different OS (supplementary figure 2d).
Novel grading algorithms based on discovery set
Multivariate analysis including all parameters exhibiting a significant association with OS (Table 1 ) was performed to develop grading models that could be compared with the current 2016 CNS WHO standard. Three different models were generated. The first approach (Model path ) aimed at minimizing the required molecular data input, which would presumably allow for the most widespread applicability. In addition to IDH and 1p/19q testing, the first approach only requires the determination of CDKN2A/B status. The second approach, Model CNVL made use of all molecular data available. Because Model CNVL in the discovery set placed a set of seven patients with necrosis into the most favorable group, we created a Model combined , which shifted these patients to the patient group with intermediate OS (Fig. 2 ). While this model was not based on a mathematical procedure, it worked well in the discovery and all validation sets.
Model path demonstrated that an algorithm based on employment of absence/presence of homozygous CDKN2A/B deletion and absence/presence of necrosis formed three groups among the 211 tumors in the discovery cohort. In this Model path , patients with homozygous deletion of CDKN2A/B exhibited the worst OS and were termed astrocytoma, IDH-mutant, grade 4, pathology (A4 path ). This group comprised 38 tumors of the discovery cohort and contained 23 GBM IDHmut and 15 AAIII IDHmut . Tumors with necrosis but without homozygous CDKN2A/B deletion fared significantly better and were termed astrocytoma, IDHmutant, grade 3, pathology (A3 path ). A3 path contained 44 tumors which by definition were all GBM IDHmut . The remaining 129 patients with neither homozygous CDKN2A/B deletion nor necrosis were termed astrocytoma, IDH-mutant, grade 2, pathology (A2 path ). A2 path contained 75 AAIII IDHmut and 54 AII IDHmut . OS plots of the discovery set assembled according to 2016 CNS WHO and according to Model path are shown (Fig. 3a, b) . Model path performed better in predicting OS of the groups than the 2016 CNS WHO did as illustrated by Brier scores (Fig. 4a) .
Model CNVL relied on absence/presence of homozygous CDKN2A/B deletion and on a threshold value of 350 Mb for CNVL. Therefore, A4 were determined as in our first approach. However, the remaining patients were subdivided with those having a CNV-L value < 350 Mb being termed astrocytoma, IDH-mutant, grade 2, CNVL (A2 CNVL ) and those with value > 350 Mb being termed astrocytoma, IDH-mutant, grade 3, CNVL (A3 CNVL ). A2 CNVL featured 86 patients containing 7 GBM IDHmut , 42 AAIII IDHmut and 37 AII IDHmut . A3 CNVL contained 87 patients, with 37 GBM IDHmut , 33 AAIII IDHmut and 17 AII IDHmut . A OS plot of the discovery set according to Model CNVL is shown (Fig. 3c) . than the 2016 CNS WHO did as illustrated by Brier scores (Fig. 4a) .
Model combined was devised to circumvent the provocative shift of patients with necrosis but without CDKN2A/B deletion and with a low CNVL into the most favorable patient group (Fig. 2) . Instead, this patient group was placed in the intermediate malignancy group. Notably, Model combined is not based on a strict mathematical approach. The number of only seven patients in this group is too small to confirm OS comparable to that of patients in the intermediate malignancy group (supplementary figure 3) . In Model combined the A4 group defined by homozygous CDKN2A/B deletion was identical to that in Model path and Model CNVL . Model combined also performed better in predicting OS of the groups than the 2016 CNS WHO could accomplish as illustrated by Brier scores (Fig. 4a) .
Importantly, all three-tiered grading approaches, i.e. WHO, Model path , Model CNVL and Model combined were predictive with higher power than two-tiered approaches based on unsupervised clustering and the classifier tool (Fig. 4a) .
Validation of the study series
The validation sets supported our findings from the discovery set.
In the HD validation set, WHO-based separation was of borderline significance (p = 0.05) (Fig. 3e) . In contrast, Model path or Model CNVL both significantly separated three prognostic patient groups (p < 0.0001) (Fig. 3f, g ). Best performance was achieved by Model combined (Fig. 3h) .
The EORTC validation set produced comparable results (Fig. 3i-l) . Here, the 2016 CNS WHO did separate groups with different OS (p = 0.004). Model path performed slightly better (p = 0.002), however, Model CNVL and Model combined again provided best separation into groups of different OS (p < 0.0001).
The TCGA dataset was only of limited value for validating our models due to a high number of cases with relatively short observation periods. We observed a good separation of patients recognized by our models as highly malignant due to the presence of a homozygous CDKN2A/B deletion. TCGA patients with CDKN2A/B homozygous deletion also died relatively quickly, and therefore, separated significantly from patients without such deletion. However, the separation between the intermediate and more favorable tumor groups was not possible due to a high number of patients lacking long-term follow-up. Thus, due to its composition, the TCGA validation set only could be used for validating the poor OS of patients with homozygous CDKN2A/B deletion (Fig. 3m-p) .
In conclusion, in all three validation sets the tested grading models performed better than the current WHO system.
Discussion
Using combined histological and genetic parameters, notably necrosis and CDKN2A/B deletion, we have established a novel grading system for IDH-mutant diffuse astrocytic tumors. Interestingly, this system does not incorporate morphological estimates of proliferation, which have been a key parameter in WHO grading systems through counting mitotic figures. Indeed, CDKN2A/B homozygous deletion is tightly linked to proliferation because loss of p16 removes the inhibition of complexes of CDK4 with D-type cyclins thereby driving the cell cycle. In our discovery set CDKN2A/B homozygous deletion was clearly associated with higher proliferation. However, a considerable fraction of patients lacking the deletion still exhibited high Ki-67 reads (supplementary figure 4) .
By focusing on this marker rather than quantifying proliferation, grading accuracy may improve because the difficulties underlying precise determination of mitotic counts (e.g., interobserver variations, tissue artifacts, interfering staining conditions, sampling, or extended time from tissue removal to fixation) are eliminated.
In our discovery set, mitotic count was not a strong predictor of outcome. This confirms previous reports pointing to the failure of morphological proliferation assessment in predicting clinical outcome in IDH-mutant astrocytic gliomas [20, 28] . Likewise, Ki67 staining ubiquitously used as a parameter for estimating proliferation provides variable readouts dependent on staining or processing conditions and, therefore, is problematic for the determination of cutoff values to discern malignancy grades.
Proliferation assessed by Ki-67 is described as low or absent in AII IDHmut in the 2016 CNS WHO 2016 [17] . In our discovery set, Ki-67 is significantly associated prognosis, but the split point was determined around 15%. A reason for the failure of Ki-67 as a prognostic parameter in WHO is the low split point (often near 2%) in the previous studies [11, 15] . These studies all were from the pre-IDH era and contained many glioblastomas, thus driving the split points to low values. This may explain why the 2016 CNS WHO stated that Ki-67 was not prognostic for AAIII IDHmut [17] . 
The presence of homozygous CDKN2A/B deletion turned out to be the most powerful parameter for inferior clinical outcome. This parameter is currently not employed in WHO grading, but could be construed as a molecular estimate of proliferation given the role of the p16 protein in regulating the cell cycle. Interestingly, CDKN2A/B homozygous deletion in tumors without necrosis, graded AAIII IDHmut , was associated with OS indistinguishable from that of patients with tumors exhibiting both CDKN2A/B homozygous deletion and necrosis that were diagnosed by definition as GBM IDHmut (Fig. 1b) . And in turn, by removing tumors with CDKN2A/B homozygous deletion among AAIII IDHmut , OS of the remaining patients did not significantly (p = 0.124) differ from that of AII IDHmut (Fig. 1b) . CDKN2A/B homozygous deletion or mutations in the RB pathway have been determined as an unfavorable parameter in previous studies [1, 26] . We therefore, performed an analysis combining cases with either CDKN2A/B homozygous deletion or RB1 homozygous deletion or CDK4 or CDK6 amplification. However, this did not result in an overall improvement of separating groups of patients with different outcome in all tumor sets. We think this is partly due to the more pronounced association of CDKN2A/B homozygous deletion with survival than that of the other RB1 pathway genes analyzed (supplementary figure 5) . While combining typical lesions of the RB1 pathway should be further explored, we expect that mainly the assessment of CDKN2A/B status will be highly relevant for future diffuse astrocytoma grading systems. Satisfactory data acquisition can be performed by FISH, by quantitative PCR or by array technology as performed in this study. As shown elsewhere, CDKN2A/B status may be readily determined by FISH analysis [23, 25] . Given the utility of immunohistochemistry for routine pathology diagnosis, we tried to detect homozygous deletion of the CDKN2A gene product p16 by immunohistochemistry. Unfortunately, using p16 antibody cloneG175-405 (BDBiosciences) we could not show satisfactory correlation between p16 immunohistochemistry and molecular detection of CDKN2A/B homozygous deletion. In our immunohistochemistry, the basal nuclear expression of p16 was too low in many samples to allow definite detection of loss of expression. Our observation is supported by another study observing a correlation of p16 expression loss and CDKN2A deletion, however, only in 85% of the deleted tumors [25] . We consider this correlation not tight enough and, therefore, favor determination of CDKN2A/B deletion by an assay addressing DNA directly. A representative CNP with evident CDKN2A/B homozygous deletion is shown in supplementary figure 6 .
Another key parameter, the presence of necrosis, which according to the 2016 CNS WHO results in the diagnosis of GBM IDHmut , appears overrated in terms of estimating prognosis in IDH-mutant diffuse astrocytomas. As a single factor, necrosis is prognostically highly significant in our discovery set (Table 1 ), but the presence of necrosis in the absence of homozygous CDKN2A/B deletion was associated with clearly better prognosis than that of tumors containing the homozygous deletion (Fig. 1b) . To account for these observations, we developed grading models based on those parameters that turned out to predict clinical outcome better than grading according to the 2016 CNS WHO (Fig. 2) . Better outcome prediction could be confirmed in two independent validation series and better detection of patients at risk for poor OS could be achieved in the TCGA set with shorter observation periods only (Fig. 3) . Our data on the TCGA data are in line with a previous study on the TCGA LGG data set reporting that CDKN2A homozygous deletion, but not expression associates with unfavorable OS [29] . Because all three tiered grading approaches in this study predicted OS with less error than the two-tiered grading schemes emerging from unsupervised clustering or from using the methylation-based classifier [5] , the latter were not further considered, although both schemes proved stable in the validation series (Fig. 4a, b and supplementary figure 2a, b, c,  d , e, f and 5).
An interesting parameter emerging from our analysis was CNVL. A proportion higher than 350 Mb either lost or gained in the areas covered by the methylation arrays correlated with poorer OS. Previously, the mutational load has been shown to correlate with tumor grade in IDH-mutant glioma [9] . While our data more reflect genomic instability and those data rely on an accumulation of mutations they also support a quantitative approach to tumor grading.
Shifts of patients according to different grading approaches
WHO grading and our grading models result in three different groups, however, with different distributions. The allotment of patients in the discovery set to model-specific sets is provided in supplementary table 1. Our novel approaches lead to a higher overall number of diffuse astrocytomas in the lower grade group. This effect is more pronounced for Model path than for Model CNVL . In Model path , the increase from 54 AII IDHmut to 129 A2 path comes with the reduction of median OS from 7053 to 5122 days. In contrast, the increase from 54 AII IDHmut to 86 A2 CNVL did not alter the median OS of 7053 days. The shifts in patient numbers in the comparable groups is mainly due to the strong influence of proliferation rate on the WHO grading algorithm. The typical problem is exemplified by a well differentiated diffuse astrocytoma being currently diagnosed as a WHO grade III tumor because of the detection of a few mitotic figures. In such a setting, the clinician may be surprised by a grade III designation given the lack of neuroradiological or intraoperative evidence for higher grade. The novel grading approaches described here appear to address this clinicopathological problem. It should be noted that the diagnostic considerations underlying WHO grading of the discovery set already deviated from the traditional WHO guidelines due to the experience of the authors who diagnosed and graded the tumors [20, 28] . In particular, more than single mitoses were accepted as compatible with AII IDHmut . In the setting of IDH mutations, the presence of few mitotic figures did not result in a diagnosis of AAIII IDHmut . This may be another reason for "standard" grading successfully predicting OS in the discovery set.
Our data demonstrate that AAIII IDHmut stratified for CDKNA/B homozygous deletion separates into two groups with quite different OS: patients with tumors lacking this alteration follow a moderately aggressive course while patients with tumors having a CDKN2A/B deletion fare more similar to patients with GBM IDHmut with homozygous deletion but much worse than patients with GBM IDHmut lacking CDKN2A/B homozygous deletion (Fig. 1b) . Thus, combining patients with AII IDHmut and AAIII IDHmut but lacking homozygous deletion of CDKN2A/B into a single group in Model path forms a fairly homogenous cohort and may have implications for the nomenclature of these tumors as well as a potential therapeutic relevance.
Model path results in reduction of the size of the intermediate grading group. In the discovery set, AAIII IDHmut with 90 patients constitutes the largest group. The equivalent group according to Model path includes 44 patients. This contrasts Model CNVL which allots 87 patients to the intermediate group. The relation of the A3 path and A3 CNVL groups is analyzed in Model combined based on CDKN2A/B, necrosis and CNVL ( Fig. 3b-d) . The power of this model is best exemplified by the lowest prediction error rate as shown by Brier score (Fig. 4a for discovery set, Fig. 4b for HD-validation set).
Implication for the use of morphological parameters, proliferation and necrosis
Our data challenge the value of two main criteria that have long been used in the grading of diffuse astrocytomas: proliferation and necrosis. As previously reported [20] , mitotic count is of less significance in a set of IDH-mutant diffuse astrocytomas than in a set of diffuse astrocytomas not tested for IDH status (and thereby likely to contain a substantial fraction of biological glioblastomas). In our analyses, mitotic figures did not emerge as a parameter providing the most significant separation of patients with IDH-mutant diffuse astrocytoma in groups with different OS. We, therefore, suggest a more conservative use of proliferation and caution to use this as a sole indicator for high tumor grade.
The other grading parameter in question is necrosis. The presence of necrosis in a diffuse astrocytic neoplasm that had not been pretreated inevitably prompted the WHO diagnosis of GBM IDHmut . However, patients with tumors exhibiting necrosis but not containing homozygous CDKN2A/B deletion survive significantly better than patients with tumors lacking necrosis but containing a CDKN2A/B homozygous deletion (Fig. 1b) . This observation in our discovery and validation series (Fig. 3) should prompt a more conditional approach to the presence of necrosis as a parameter for grading of higher-grade diffuse astrocytic tumors.
Clinical perspective of grading according to the novel approaches
Caveats of our study are the heterogeneity of treatment and the potential effect of treatment on OS. Patients with AAIII IDHmut and AII IDHmut .have been treated quite heterogeneously with therapies ranging from wait and see to radiotherapy, chemotherapy or combinations thereof. In general, patients with AAIII IDHmut may have been likely to receive a more intense treatment than patients with AII IDHmut . We cannot exclude the possibility of treatment being effective in patients with AAIII IDHmut , thereby blurring the distinction to OS of patients with AII IDHmut . Nonetheless, the current treatment for AII IDHmut and AAIII IDHmut is similar in most centers. Therefore, the shift of patients between the corresponding groups following grading according to our novel approaches will likely not have an immediate effect on treatment. However, upon applying Model combined we subdivide AII IDHmut into A2 combined and A3 combined . Patients with A2 combined , although more numerous than those in AII IDHmut , appear to exhibit a slightly better OS than patients with AII IDHmut . This may prompt future consideration regarding therapy in A2 combined patients. In contrast, patients with A3 combined show average OS closer to AAIII IDHmut patients, thereby potentially supporting similar treatments for these groups. In turn, it will be of interest to determine if patients with GBM IDHmut should receive the same treatment as those patients with GBM IDHmut lacking homozygous CDKN2A/B deletion since these patients have OS approaching that of AAIII IDHmut . Finally, patients assigned to the least favorable A4 group all exhibit homozygous CDKN2A/B deletion; such patients are in need of maximal treatment and could possibly benefit from treatment with CDK antagonists because CDKN2A/B deletion results in increased CDK activity [24] .
Implications for the classification and grading of IDH-mutant diffuse astrocytic tumors
The 2016 CNS WHO divided the traditionally termed "glioblastoma" into GBM IDHwt , GBM IDHmut and, in specific situations, diffuse midline glioma, H3K27-mutant. Genetically, these three groups are entirely different. While the diffuse midline glioma, H3K27-mutant is semantically clearly set apart from GBM IDHwt , the latter shares the same "family name" with GBM IDHmut [18] . However, there appears to be greater genetic kinship between GBM IDHmut and A IDHmut and not between GBM IDHmut and GBM IDHwt . This kinship is also supported by the distribution of other mutations such as ATRX or TP53 that are typically seen in these tumors and by the rarity of many mutations typical for GBM IDHwt such as EGFR amplification. Thus a genetic approach to taxonomy would favor a term such as "high-grade A IDHmut " rather than the current term of GBM IDHmut .
However, this still would be in conflict with a harmonious grading scale. Clearly, GBM IDHmut has a better prognosis than GBM IDHwt . In fact, GBM IDHmut has a better prognosis than the prognosis allotted to the pre-IDH era anaplastic astrocytoma WHO grade III (AAIII NOS ) [34] . This circumstance would argue for a lower grade than currently allotted to the GBM IDHmut . However, the novel creation of an IDHmutant glioblastoma grade 3 would seem awkward [18] .
We suggest that future grading approaches include assessment of homozygous CDKN2A/B deletion in these tumors, given its powerful association with poorer prognosis. This accounts for both GBM IDHmut and AAIII IDHmut -resulting in essential irrelevance of the presence of necrosis on OS in tumors with homozygous CDKN2A/B deletion. In other words, a definable fraction of AAIII IDHmut fare significantly worse than a fraction of the GBM IDHmut . This cannot be repaired using the current WHO nomenclature without major changes to our historical concepts of nomenclature [18] .
One possible solution, which we have considered implementing in Heidelberg, would be to restrict classification to the term A IDHmut and then adapt grading according to molecular lesions, thereby omitting the term GBM IDHmut . The term "glioblastoma" would be reserved for those histologically defined glioblastomas lacking IDH mutation or not having had adequate (not otherwise specified, NOS) or diagnostic (not elsewhere classified, NEC) work-ups [19] . Such a system would lend itself well to the use of layered reports, as discussed elsewhere [16] . In this context, if these data were confirmed in other studies, the WHO classification of such tumors could resemble what is given in supplementary Table 2 (based on Model path ). Advantages of such an approach would include better prognostic correlations and therefore guidance of therapies, and a "freeing up" of grading from classification that could allow more easy adaptation of grading criteria in the future [18] .
Conclusions
The 2016 CNS WHO grading of IDH-mutant astrocytic tumors is not as prognostically meaningful as needed and the histological parameters of proliferation and necrosis appear overrated when incorporating IDH gene status. Significantly, several other morphological and molecular parameters show higher prognostic power and modeling has provided suggestions for grading algorithms, with the proposal that CDNK2A/B status will be important for future grading of these tumors.
